NextCell Pharma AB
STO: NXTCL.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mathias Svahn
- Employees
- 24
- Headquarters
- Huddinge, Sweden
- IPO year
- 2017
- Market cap
- SEK 137.0M
- Website
- https://www.nextcellpharma.com
Loading NXTCL…
Loading profile data…Frequently asked questions about NXTCL
What does NextCell Pharma AB (NXTCL.ST) do?
NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from u...
Where does NXTCL.ST trade?
NextCell Pharma AB (NXTCL.ST) trades on the Stockholm Stock Exchange.
What sector is NXTCL.ST in?
NextCell Pharma AB (NXTCL.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NextCell Pharma AB?
Mathias Svahn is the chief executive officer of NextCell Pharma AB (NXTCL.ST).
Where is NextCell Pharma AB headquartered?
NextCell Pharma AB is headquartered in Sweden.
Does NXTCL.ST pay a dividend?
NextCell Pharma AB (NXTCL.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NXTCL.ST go public?
NextCell Pharma AB (NXTCL.ST) completed its initial public offering in 2017.